SABCS: Active Monitoring Noninferior to Guideline Care for Ductal Carcinoma in Situ
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 13, 2024 -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) that involves surgery with or without adjuvant radiation, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.
E. Shelley Hwang, M.D., M.P.H., from the Duke University School of Medicine in Durham, North Carolina, and colleagues examined the outcomes of 995 participants with grade 1 or 2 hormone receptor-positive, human epidermal growth factor receptor 2-negative DCIS enrolled in the Comparing an Operation to Monitoring, with or without Endocrine Therapy for low risk DCIS trial who were randomly assigned to GCC (473 patients) or AM (484 patients). Participants in the AM group underwent surgical intervention only upon invasive progression diagnosis, or they could elect to have surgery at any time. Patients were allowed to receive endocrine therapy if desired, in both treatment arms.
The researchers found that 27 patients in the GCC arm and 19 in the AM arm had been diagnosed with invasive ipsilateral breast cancer after 24 months of follow-up. The two-year cumulative rate of invasive ipsilateral breast cancer was 5.9 and 4.2 percent for the GCC and AM arms, respectively, meeting the threshold for noninferiority. More patients in the AM versus GCC arm received endocrine therapy (71.3 versus 65.5 percent). Of those receiving endocrine therapy, invasive ipsilateral cancer was seen in 7.15 percent of patients in the GCC arm and 3.21 percent in the AM arm.
"Omission of surgery has been highly controversial, with both patients and providers fearing that it might result in an unacceptably high rate of patients who develop invasive cancer," Hwang said in a statement. "Our findings are reassuring, and longer-term follow up will have important implications for the future inclusion of active monitoring as a treatment option for low-risk DCIS."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
MONDAY, March 3, 2025 -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4)...
Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors
MONDAY, March 3, 2025 -- For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium-glucose co-transporter (SGLT)-1/2...
Psychosomatic Misdiagnosis Can Have Lasting Negative Impact on Patients
MONDAY, March. 3, 2025 -- Chronic diseases misdiagnosed as psychosomatic can lead to long-term damage to patients' physical and mental well-being, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.